Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 1
2011 3
2012 8
2013 1
2017 2
2018 1
2019 4
2020 1
2021 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial.
Belperio J, Nguyen T, Lombardi DA, Bogus M, Moskalenko V, Singh D, Haumann B, Bourdet DL, Kaufman E, Pfeifer ND, Thompson CG, Woo J, Moran EJ, Saggar R. Belperio J, et al. Among authors: haumann b. BMJ Open Respir Res. 2023 Jul;10(1):e001627. doi: 10.1136/bmjresp-2023-001627. BMJ Open Respir Res. 2023. PMID: 37460276 Free PMC article. Clinical Trial.
The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol.
Vestbo J, Anderson J, Brook RD, Calverley PM, Celli BR, Crim C, Haumann B, Martinez FJ, Yates J, Newby DE. Vestbo J, et al. Among authors: haumann b. Eur Respir J. 2013 May;41(5):1017-22. doi: 10.1183/09031936.00087312. Epub 2012 Sep 27. Eur Respir J. 2013. PMID: 23018908 Free article. Clinical Trial.
A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19.
Singh D, Bogus M, Moskalenko V, Lord R, Moran EJ, Crater GD, Bourdet DL, Pfeifer ND, Woo J, Kaufman E, Lombardi DA, Weng EY, Nguyen T, Woodcock A, Haumann B, Saggar R. Singh D, et al. Among authors: haumann b. Eur Respir J. 2021 Oct 14;58(4):2100673. doi: 10.1183/13993003.00673-2021. Print 2021 Oct. Eur Respir J. 2021. PMID: 34210790 Free PMC article. Clinical Trial.
Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease.
Donohue JF, Kerwin E, Sethi S, Haumann B, Pendyala S, Dean L, Barnes CN, Moran EJ, Crater G. Donohue JF, et al. Among authors: haumann b. Respir Med. 2019 Jul;153:38-43. doi: 10.1016/j.rmed.2019.05.010. Epub 2019 May 23. Respir Med. 2019. PMID: 31150963 Free article. Clinical Trial.
Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
Quinn D, Barnes CN, Yates W, Bourdet DL, Moran EJ, Potgieter P, Nicholls A, Haumann B, Singh D. Quinn D, et al. Among authors: haumann b. Pulm Pharmacol Ther. 2018 Feb;48:71-79. doi: 10.1016/j.pupt.2017.10.003. Epub 2017 Oct 4. Pulm Pharmacol Ther. 2018. PMID: 28987804 Free article. Clinical Trial.
22 results